Quest Diagnostics 2008 Annual Report Download - page 117
Download and view the complete annual report
Please find page 117 of the 2008 Quest Diagnostics annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107 -
108 -
109 -
110 -
111 -
112 -
113 -
114 -
115 -
116 -
117 -
118 -
119 -
120 -
121 -
122 -
123 -
124 -
125 -
126 -
127 -
128
 |
 |
(e) In the third quarter of 2008, the Company recorded a $8.9 million charge associated with the write-down of
an equity investment.
(f) In the fourth quarter of 2008, the Company recorded $16.2 million of costs, primarily associated with
workforce reductions.
(g) In the third quarter of 2008, the Company recorded a charge of $73 million associated with the government’s
investigation in connection with NID (see Note 14).
(h) In the first quarter of 2007, the Company recorded $10.7 million of costs associated with workforce
reductions and a $4 million charge related to in-process research and development expense associated with
the acquisition of HemoCue.
(i) In the fourth quarter of 2007, the Company recorded a charge of $4.0 million associated with the write-down
of an equity investment.
(j) In the third and fourth quarters of 2007, the Company recorded a charge of $51 million and $190 million,
respectively, associated with the government’s investigation in connection with NID (see Note 14).
F-45